Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
Sleep/wakefulness (S/W) disorders are frequent in Parkinson's disease (PD). The underlying causes have yet to be elucidated but dopaminergic neurodegenerative lesions seem to contribute to appearance of the disorders and anti-Parkinsonian medication is known to accentuate S/W problems. Hence, we reasoned that studying the acute effect of dopaminergic compounds on S/W in an animal model of PD might improve our knowledge of S/W regulation in the context of partial dopaminergic depletion. To this end, we tested the effect of levodopa (l-dopa), pergolide (a mixed D(2)/D(1) agonist) and lisuride (a D(2) agonist) on S/W recordings in MPTP-treated mice, in comparison with controls. Our results showed that dopaminergic compounds modify S/W amounts in both control and MPTP mice. Wakefulness amounts are greater in MPTP mice after l-dopa (50 mg kg(-1)) and lisuride (1 mg kg(-1)) injections compared with control mice. Moreover, the paradoxical sleep latency was significantly longer in MPTP mice after high-dose l-dopa administration. Our observations suggest that the actions of both l-dopa and lisuride on S/W differ slightly in MPTP mice relative to controls. Hence, MPTP-induced partial DA depletion may modulate the effect of dopaminergic compounds on S/W regulation.
Laloux
Charlotte
C
Laboratoire de Physiologie, Institut Fédératif de Recherche, Faculté de Médecine, Pôle recherce, Lille cedex, France.
Derambure
Philippe
P
Houdayer
Elise
E
Jacquesson
Jean-Marie
JM
Bordet
Régis
R
Destée
Alain
A
Monaca
Christelle
C
D000818:Animals; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D004569:Electroencephalography; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008090:Lisuride / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D017286:Polysomnography; D012890:Sleep / Q000187:drug effects*; D014851:Wakefulness / Q000187:drug effects*
D018491:Dopamine Agonists; D010479:Pergolide; D007980:Levodopa; D008090:Lisuride